Hence, larger, randomized controlled trials that provide guidance on dose, route, frequency, and duration of therapy for definitive wound closure, specific to diabetes and other current etiologies, are needed to further confirm benefit of rhu GM-CSF. This evidence concerns the gene CSF2 and diabetes mellitus.